Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Thomas

Showing results (101-110 of 139) with videos related to

Pageof 14
Sort By:
BMJ Open|September 3, 2018
Progress in voluntary medical male circumcision for HIV prevention supported by the US President's Emergency Plan for AIDS Relief through 2017: longitudinal and recent cross-sectional programme dataStephanie M Davis, Jonas Z Hines, Melissa Habel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2019
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinomaAnne Thomas, Pradeep S Virdee, Martin Eatock, et al.
Scientific Reports|August 23, 2019
Inhibition of GATA2 restrains cell proliferation and enhances apoptosis and chemotherapy mediated apoptosis in human GATA2 overexpressing AML cellsJuan Bautista Menendez-Gonzalez, Samantha Sinnadurai, Alex Gibbs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumorsAndreas H Jacobs, Anne Thomas, Lutz W Kracht, et al.
Cells|March 27, 2026
Microglial-Targeted GCPII Inhibition Reverses Neurocognitive Impairment and Synaptic Loss After EcoHIV InfectionYuxin Zheng, Meixiang Huang, R Michael Maragakis, et al.
The Journal of Dermatological Treatment|April 25, 2015
Long-term use of a 4% sodium cromoglicate cutaneous emulsion in the treatment of moderate to severe atopic dermatitis in childrenAlan Martin Edwards, Dalia Bibawy, Sharon Matthews, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trialDean A Fennell, Amy King, Seid Mohammed, et al.
Health Technology Assessment (Winchester, England)|March 21, 2024
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCTVicky Coyle, Caroline Forde, Richard Adams, et al.
Plos Genetics|March 23, 2018
MKLN1 splicing defect in dogs with lethal acrodermatitisAnina Bauer, Vidhya Jagannathan, Sandra Högler, et al.
The Lancet. Oncology|June 27, 2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 studyTimothy Iveson, Ross C Donehower, Irina Davidenko, et al.
Pageof 14

Showing results (101-110 of 139) with videos related to

Sort By:
Pageof 14
BMJ Open|September 3, 2018
Progress in voluntary medical male circumcision for HIV prevention supported by the US President's Emergency Plan for AIDS Relief through 2017: longitudinal and recent cross-sectional programme dataStephanie M Davis, Jonas Z Hines, Melissa Habel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2019
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinomaAnne Thomas, Pradeep S Virdee, Martin Eatock, et al.
Scientific Reports|August 23, 2019
Inhibition of GATA2 restrains cell proliferation and enhances apoptosis and chemotherapy mediated apoptosis in human GATA2 overexpressing AML cellsJuan Bautista Menendez-Gonzalez, Samantha Sinnadurai, Alex Gibbs, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumorsAndreas H Jacobs, Anne Thomas, Lutz W Kracht, et al.
Cells|March 27, 2026
Microglial-Targeted GCPII Inhibition Reverses Neurocognitive Impairment and Synaptic Loss After EcoHIV InfectionYuxin Zheng, Meixiang Huang, R Michael Maragakis, et al.
The Journal of Dermatological Treatment|April 25, 2015
Long-term use of a 4% sodium cromoglicate cutaneous emulsion in the treatment of moderate to severe atopic dermatitis in childrenAlan Martin Edwards, Dalia Bibawy, Sharon Matthews, et al.
The Lancet. Respiratory Medicine|January 30, 2021
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trialDean A Fennell, Amy King, Seid Mohammed, et al.
Health Technology Assessment (Winchester, England)|March 21, 2024
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCTVicky Coyle, Caroline Forde, Richard Adams, et al.
Plos Genetics|March 23, 2018
MKLN1 splicing defect in dogs with lethal acrodermatitisAnina Bauer, Vidhya Jagannathan, Sandra Högler, et al.
The Lancet. Oncology|June 27, 2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 studyTimothy Iveson, Ross C Donehower, Irina Davidenko, et al.
Pageof 14